Listed

Vaxcyte, Inc.: Form 10-K for the period ended Dec 31, 2022

Filed with the SEC on Feb 27, 2023 and accepted by EDGAR at Feb 27, 2023, 16:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2022-01-01 to 2022-12-31$169.5mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2022-01-01 to 2022-12-31−$232.3mus-gaap:OperatingIncomeLoss
Interest expense12 months2022-01-01 to 2022-12-31$2.0kus-gaap:InterestExpense
Net income12 months2022-01-01 to 2022-12-31−$223.5mus-gaap:NetIncomeLoss
Diluted EPS12 months2022-01-01 to 2022-12-31−$3.44us-gaap:EarningsPerShareDiluted
Basic EPS12 months2022-01-01 to 2022-12-31−$3.44us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2022-01-01 to 2022-12-3164,877,988 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2022-01-01 to 2022-12-31−$170.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2022-01-01 to 2022-12-31$5.8mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-12-31$834.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-12-31$942.6mus-gaap:AssetsCurrent
Total assetsAt period end2022-12-31$1.01bnus-gaap:Assets
Current liabilitiesAt period end2022-12-31$40.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-12-31$52.6mus-gaap:Liabilities
Shareholders' equityAt period end2022-12-31$953.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-23-004654. Last ingested by Listed: Nov 2, 2026, 17:26 ET. Listed shows no prices and gives no investment advice.